Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/DLG5_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/DLG5_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DLG5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DLG5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DLG5_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DLG5_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DLG5_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DLG5_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00017384 | Cervix | CC | morphogenesis of a polarized epithelium | 22/2311 | 94/18723 | 2.09e-03 | 1.52e-02 | 22 |
GO:00353294 | Cervix | CC | hippo signaling | 12/2311 | 40/18723 | 2.44e-03 | 1.71e-02 | 12 |
GO:00303235 | Cervix | CC | respiratory tube development | 36/2311 | 181/18723 | 2.46e-03 | 1.71e-02 | 36 |
GO:0070664 | Cervix | CC | negative regulation of leukocyte proliferation | 21/2311 | 90/18723 | 2.71e-03 | 1.85e-02 | 21 |
GO:00605413 | Cervix | CC | respiratory system development | 39/2311 | 203/18723 | 3.18e-03 | 2.07e-02 | 39 |
GO:00605626 | Cervix | CC | epithelial tube morphogenesis | 57/2311 | 325/18723 | 3.79e-03 | 2.41e-02 | 57 |
GO:0050672 | Cervix | CC | negative regulation of lymphocyte proliferation | 19/2311 | 83/18723 | 5.25e-03 | 3.08e-02 | 19 |
GO:00018374 | Cervix | CC | epithelial to mesenchymal transition | 31/2311 | 157/18723 | 5.25e-03 | 3.08e-02 | 31 |
GO:00343326 | Cervix | CC | adherens junction organization | 13/2311 | 49/18723 | 5.34e-03 | 3.10e-02 | 13 |
GO:00017636 | Cervix | CC | morphogenesis of a branching structure | 37/2311 | 196/18723 | 5.36e-03 | 3.10e-02 | 37 |
GO:0032945 | Cervix | CC | negative regulation of mononuclear cell proliferation | 19/2311 | 84/18723 | 6.02e-03 | 3.43e-02 | 19 |
GO:00604412 | Cervix | CC | epithelial tube branching involved in lung morphogenesis | 9/2311 | 29/18723 | 6.49e-03 | 3.61e-02 | 9 |
GO:0042130 | Cervix | CC | negative regulation of T cell proliferation | 16/2311 | 67/18723 | 6.51e-03 | 3.61e-02 | 16 |
GO:00519622 | Cervix | CC | positive regulation of nervous system development | 48/2311 | 272/18723 | 6.60e-03 | 3.65e-02 | 48 |
GO:00487624 | Cervix | CC | mesenchymal cell differentiation | 42/2311 | 236/18723 | 9.12e-03 | 4.60e-02 | 42 |
GO:00353301 | Cervix | CC | regulation of hippo signaling | 7/2311 | 21/18723 | 1.04e-02 | 4.97e-02 | 7 |
GO:000716320 | Esophagus | ESCC | establishment or maintenance of cell polarity | 143/8552 | 218/18723 | 2.05e-09 | 4.65e-08 | 143 |
GO:00303239 | Esophagus | ESCC | respiratory tube development | 112/8552 | 181/18723 | 7.82e-06 | 7.69e-05 | 112 |
GO:006056210 | Esophagus | ESCC | epithelial tube morphogenesis | 187/8552 | 325/18723 | 9.95e-06 | 9.44e-05 | 187 |
GO:00605417 | Esophagus | ESCC | respiratory system development | 123/8552 | 203/18723 | 1.26e-05 | 1.15e-04 | 123 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DLG5 | SNV | Missense_Mutation | | c.2146N>C | p.Val716Leu | p.V716L | Q8TDM6 | protein_coding | tolerated(0.55) | benign(0.005) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
DLG5 | SNV | Missense_Mutation | rs750819054 | c.1496N>A | p.Arg499Gln | p.R499Q | Q8TDM6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
DLG5 | SNV | Missense_Mutation | rs200259340 | c.2038G>A | p.Asp680Asn | p.D680N | Q8TDM6 | protein_coding | tolerated(0.39) | probably_damaging(1) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
DLG5 | SNV | Missense_Mutation | novel | c.3988N>C | p.Val1330Leu | p.V1330L | Q8TDM6 | protein_coding | tolerated(0.14) | benign(0.071) | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | | SD |
DLG5 | SNV | Missense_Mutation | rs372158883 | c.1354N>A | p.Glu452Lys | p.E452K | Q8TDM6 | protein_coding | tolerated(0.17) | possibly_damaging(0.795) | TCGA-A8-A08B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
DLG5 | SNV | Missense_Mutation | rs753964604 | c.4343N>T | p.Gly1448Val | p.G1448V | Q8TDM6 | protein_coding | deleterious(0.03) | benign(0.024) | TCGA-AN-A0FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DLG5 | SNV | Missense_Mutation | rs753964604 | c.4343G>T | p.Gly1448Val | p.G1448V | Q8TDM6 | protein_coding | deleterious(0.03) | benign(0.024) | TCGA-AR-A0TQ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
DLG5 | SNV | Missense_Mutation | rs753964604 | c.4343G>T | p.Gly1448Val | p.G1448V | Q8TDM6 | protein_coding | deleterious(0.03) | benign(0.024) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR |
DLG5 | SNV | Missense_Mutation | rs753964604 | c.4343N>T | p.Gly1448Val | p.G1448V | Q8TDM6 | protein_coding | deleterious(0.03) | benign(0.024) | TCGA-C8-A135-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
DLG5 | SNV | Missense_Mutation | rs753964604 | c.4343N>T | p.Gly1448Val | p.G1448V | Q8TDM6 | protein_coding | deleterious(0.03) | benign(0.024) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |